Influence of migrasome-associated long noncoding RNAs on the immune microenvironment and prognosis in lung adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Migrasome-related long noncoding RNAs (lncRNAs) can predict lung adenocarcinoma (LUAD) patient outcomes and immunotherapy response. A novel risk score model identifies patients who may benefit from immune checkpoint inhibitors.
Area Of Science
- Oncology
- Molecular Biology
- Bioinformatics
Background
- Lung adenocarcinoma (LUAD) is a major cause of cancer mortality.
- Identifying reliable prognostic biomarkers is crucial for LUAD patient management.
- The role of migrasome-related long noncoding RNAs (lncRNAs) in LUAD prognosis remains largely unexplored.
Purpose Of The Study
- To investigate the prognostic significance of migrasome-related lncRNAs in LUAD.
- To develop and validate a risk score model based on these lncRNAs for predicting patient outcomes.
- To explore the association between migrasome-related lncRNAs, tumor immune microenvironment, and immunotherapy response in LUAD.
Main Methods
- Transcriptomic data analysis from The Cancer Genome Atlas (TCGA) database.
- Correlation analysis to identify key migrasome-related lncRNAs associated with patient survival.
- Construction and validation of a prognostic risk score model using Cox regression and an independent dataset.
- Tumor Immune Dysfunction and Exclusion (TIDE) and functional enrichment analyses to assess immune features and pathways.
Main Results
- A risk score model comprising 17 migrasome-related lncRNAs was developed and validated.
- High-risk patients demonstrated significantly worse overall and progression-free survival.
- The risk score correlated with altered immune features, suggesting immune evasion and potential immunotherapy responsiveness.
- TIDE analysis indicated that higher-risk individuals might benefit more from immune checkpoint inhibitors.
Conclusions
- Migrasome-related lncRNAs serve as robust prognostic biomarkers for LUAD.
- The developed risk score model effectively predicts patient prognosis and informs immunotherapy decisions.
- These lncRNAs offer potential therapeutic targets and highlight the interplay between migrasomes, lncRNAs, and tumor immunity in LUAD.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...